Patients
Clinical trial opportunities for patients
Citryll is conducting clinical trials for CIT-013, an investigational therapy developed to address rheumatoid Arrthritis (RA) and hidradenitis suppurativa (HS). This clinical research seeks to understand CIT-013’s potential effectiveness, safety, and impact on patient quality of life.
About CIT-013 in rheumatoid arthritis and hidradenitis suppurativa
CIT-013 is designed to target specific immune responses involved in RA and HS. Our research focuses on a process called ETosis, in which certain immune cells release web-like structures, or ETs, that can lead to inflammation and tissue damage. CIT-013 aims to reduce this process, potentially lowering disease activity and inflammation in RA and HS. This approach could offer a new way to manage these conditions.
Learn more and participate
Citryll’s clinical trials aim to understand CIT-013’s effectiveness, safety and impact on patient’s quality of life.
If you or someone you know have RA or HS, participating in a clinical trial might be an option.
More detail on our current clinical trials and eligibility is available below.
Ongoing Clinical Trials
Citydream – A Study with CIT-013 in RA patients
Location:
- Netherlands, Belgium, Germany, Poland, Spain
Start:
- July - 2025
Citylights – A Study With CIT-013 in HS Patients
Location:
- Netherlands, Germany, Poland, Spain, Canada, United Kingdom
Start:
- November - 2025